Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/06/2023 | 31.19% | Piper Sandler | $210 → $215 | Maintains | Overweight |
10/30/2023 | 18.99% | Stifel | $205 → $195 | Maintains | Buy |
09/12/2023 | 25.09% | Stifel | → $205 | Reiterates | Buy → Buy |
09/06/2023 | 40.35% | HSBC | → $230 | Initiates Coverage On | → Buy |
08/28/2023 | 25.09% | Stifel | $195 → $205 | Maintains | Buy |
08/14/2023 | 34.24% | Piper Sandler | $210 → $220 | Maintains | Overweight |
08/10/2023 | 29.97% | Goldman Sachs | $204 → $213 | Maintains | Buy |
06/14/2023 | 37.3% | Atlantic Equities | → $225 | Reiterates | Overweight → Overweight |
05/26/2023 | 37.3% | Atlantic Equities | → $225 | Reiterates | Overweight → Overweight |
05/08/2023 | 28.14% | Piper Sandler | $220 → $210 | Maintains | Overweight |
02/21/2023 | 58.65% | Barclays | $250 → $260 | Maintains | Overweight |
11/15/2022 | 51.33% | Morgan Stanley | $264 → $248 | Maintains | Overweight |
11/04/2022 | 9.84% | B of A Securities | $225 → $180 | Maintains | Buy |
11/04/2022 | 9.84% | Goldman Sachs | $207 → $180 | Maintains | Buy |
10/17/2022 | 37.3% | JP Morgan | $250 → $225 | Maintains | Overweight |
07/21/2022 | 23.26% | Goldman Sachs | $208 → $202 | Maintains | Buy |
07/12/2022 | 25.09% | Piper Sandler | → $205 | Initiates Coverage On | → Overweight |
06/29/2022 | 37.3% | Stifel | $225 → $225 | Maintains | Buy |
06/24/2022 | 37.3% | Stifel | $275 → $225 | Maintains | Buy |
06/17/2022 | 22.04% | Argus Research | $225 → $200 | Maintains | Buy |
05/19/2022 | 26.92% | Goldman Sachs | $237 → $208 | Maintains | Buy |
03/09/2022 | 26.92% | Citigroup | $232 → $208 | Maintains | Neutral |
02/16/2022 | 54.99% | B of A Securities | $258 → $254 | Maintains | Buy |
01/10/2022 | 49.5% | Barclays | $240 → $245 | Maintains | Overweight |
01/07/2022 | 67.81% | Stifel | $250 → $275 | Maintains | Buy |
12/20/2021 | 41.57% | Citigroup | $184 → $232 | Maintains | Neutral |
11/18/2021 | 61.09% | Morgan Stanley | → $264 | Initiates Coverage On | → Overweight |
11/09/2021 | 49.5% | Goldman Sachs | $220 → $245 | Maintains | Buy |
11/05/2021 | 46.45% | Barclays | $235 → $240 | Maintains | Overweight |
10/27/2021 | 37.3% | B of A Securities | $225 → $225 | Maintains | Buy |
10/26/2021 | 40.35% | Stifel | $220 → $230 | Maintains | Buy |
08/09/2021 | 40.35% | Credit Suisse | $206 → $230 | Maintains | Outperform |
08/06/2021 | 43.4% | Barclays | $208 → $235 | Maintains | Overweight |
08/05/2021 | 34.24% | Stifel | $185 → $220 | Maintains | Buy |
08/04/2021 | 25.7% | Credit Suisse | → $206 | Assumes | Outperform → Outperform |
07/27/2021 | 37.3% | B of A Securities | → $225 | Maintains | Buy |
07/16/2021 | — | Raymond James | Downgrades | Outperform → Market Perform | |
05/28/2021 | 18.99% | Argus Research | $185 → $195 | Maintains | Buy |
05/12/2021 | 12.28% | Citigroup | $175 → $184 | Maintains | Neutral |
05/10/2021 | 9.84% | Truist Securities | $170 → $180 | Maintains | Hold |
05/07/2021 | 26.92% | Barclays | $200 → $208 | Maintains | Overweight |
05/07/2021 | 17.16% | Raymond James | $166 → $192 | Maintains | Outperform |
03/08/2021 | 1.29% | Raymond James | → $166 | Upgrades | Market Perform → Outperform |
03/08/2021 | 9.84% | B of A Securities | → $180 | Upgrades | Neutral → Buy |
02/17/2021 | 23.87% | Credit Suisse | $197 → $203 | Maintains | Outperform |
11/13/2020 | 6.18% | Morgan Stanley | $167 → $174 | Maintains | Equal-Weight |
11/06/2020 | 15.33% | Barclays | $175 → $189 | Maintains | Overweight |
09/21/2020 | 16.55% | Atlantic Equities | → $191 | Initiates Coverage On | → Overweight |
09/15/2020 | -2.98% | UBS | $126 → $159 | Maintains | Neutral |
08/20/2020 | 1.9% | Morgan Stanley | $125 → $167 | Maintains | Equal-Weight |
08/12/2020 | — | Gabelli & Co. | Downgrades | Buy → Hold | |
08/10/2020 | 6.79% | Barclays | $140 → $175 | Maintains | Overweight |
08/10/2020 | -2.37% | Truist Securities | $112 → $160 | Maintains | Hold |
08/10/2020 | -2.37% | Citigroup | $146 → $160 | Maintains | Neutral |
07/30/2020 | -10.91% | Citigroup | $131 → $146 | Maintains | Neutral |
07/20/2020 | -8.47% | B of A Securities | $135 → $150 | Maintains | Neutral |
05/08/2020 | -23.11% | UBS | $146 → $126 | Maintains | Neutral |
05/08/2020 | -20.06% | Citigroup | $139 → $131 | Maintains | Neutral |
05/07/2020 | -14.57% | Barclays | $129 → $140 | Maintains | Overweight |
04/02/2020 | -23.72% | Morgan Stanley | $148 → $125 | Maintains | Equal-Weight |
02/19/2020 | -10.91% | UBS | $126 → $146 | Maintains | Neutral |
02/14/2020 | -9.69% | Morgan Stanley | $136 → $148 | Maintains | Equal-Weight |
02/13/2020 | -2.37% | CFRA | $147 → $160 | Upgrades | Buy → Strong Buy |
02/12/2020 | -11.52% | B of A Securities | $138 → $145 | Maintains | Neutral |
02/10/2020 | -4.81% | Stifel | $150 → $156 | Maintains | Buy |
01/10/2020 | — | Raymond James | Initiates Coverage On | → Market Perform | |
01/09/2020 | -8.47% | Stifel | $140 → $150 | Maintains | Buy |
11/08/2019 | -8.47% | JP Morgan | $145 → $150 | Maintains | Overweight |
09/30/2019 | -17.01% | Morgan Stanley | $100 → $136 | Maintains | Equal-Weight |
08/13/2019 | -20.67% | SunTrust Robinson Humphrey | $120 → $130 | Maintains | Hold |
07/22/2019 | -20.67% | Stifel | $110 → $130 | Maintains | Buy |
07/01/2019 | -26.78% | B of A Securities | $111 → $120 | Downgrades | Buy → Neutral |
06/11/2019 | -26.78% | Barclays | → $120 | Initiates Coverage On | → Overweight |
05/09/2019 | -35.93% | BMO Capital | $101 → $105 | Maintains | Market Perform |
05/03/2019 | — | Gabelli & Co. | Downgrades | Buy → Hold | |
04/02/2019 | -31.66% | Credit Suisse | $102 → $112 | Maintains | Outperform |
03/20/2019 | -38.98% | SunTrust Robinson Humphrey | → $100 | Initiates Coverage On | → Hold |
03/04/2019 | — | Stifel | Upgrades | Hold → Buy | |
02/25/2019 | -38.37% | BMO Capital | $93 → $101 | Maintains | Market Perform |
01/23/2019 | — | UBS | Initiates Coverage On | → Neutral |
What is the target price for Zoetis (ZTS)?
The latest price target for Zoetis (NYSE: ZTS) was reported by Piper Sandler on November 6, 2023. The analyst firm set a price target for $215.00 expecting ZTS to rise to within 12 months (a possible 31.19% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Zoetis (ZTS)?
The latest analyst rating for Zoetis (NYSE: ZTS) was provided by Piper Sandler, and Zoetis maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Zoetis (ZTS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zoetis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zoetis was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
Is the Analyst Rating Zoetis (ZTS) correct?
While ratings are subjective and will change, the latest Zoetis (ZTS) rating was a maintained with a price target of $210.00 to $215.00. The current price Zoetis (ZTS) is trading at is $163.88, which is out of the analyst's predicted range.